Work Package 5: Complex and poor prognosis cancer
Some cancers, such as pancreatic cancer, gastric cancer and head and neck cancers, are considered as poor-prognosis cancers, due to their high mortality rates (>20 per 100,000/year) and low survival (relative survival ≤40% at 1 year, ≤30% at 3 or 5 years after diagnosis). The goal of WP5 will be to establish at least a NoE dedicated to one complex/poor prognosis cancer to increase the efficacy of treatments and quality of care, reduce inequality across the EU, boost basic/preclinical research and the use of innovative technologies, promote education, clinical practice guidelines and multidisciplinary care development, as well as epidemiological surveillance. Since some poor-prognosis cancers fall within cancers which are already covered, at least in part, by existing ERNs (namely, EURACAN), a discussion with stakeholders will be held to decide whether some poor-prognosis cancers may be added to EURACAN’s domains already in place (with regard to head & neck cancers).
The specific objectives include the definition of:
- the scope of the NoE
- the activities of the NoE
- potential partners
- governance
- sustainability
- indicators of efficacy and cost/efficacy
- interplay with MSs, networks, CCCs, EU patients
Lead Beneficiary: Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie – Panstwowy Instytut Badawczy (MSCI)
WP5 6-month update (October 2022-March 2023)
Activities:
- The Framework for pilot poor prognosis Network of Expertise (NoE) was established.
- The list of experts was created.
- The decision by the experts group was made to base the pilot poor prognosis cancer NoE on pancreatic cancer.
- The scope of pilot pancreatic cancer NoE was defined.
Meetings:
- JANE Kick-off Meeting, 14-15 November 2022, Milan, Italy
- JANE WP5 online meeting, 24th of January 2023, Expert discussion on the selection of the cancer type for creating a pilot network for poor prognosis cancer NoE.
- JANE and CraNE synergy meeting
- JANE WP5 online meeting, 30th of March 2023, Definition of the scope of NoE for pilot pancreatic cancer
Priorities for the next semester:
- NoE Governance development
- Identification of the endorsement criteria for pilot pancreatic cancer NoE
WP5 12-month update (October 2022-September 2023)
